PortfoliosLab logo
Cortexyme Inc (QNCX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

IPO Date

May 9, 2019

Highlights

Market Cap

$47.29M

EPS (TTM)

-$1.39

Total Revenue (TTM)

$168.00K

Gross Profit (TTM)

$40.00K

EBITDA (TTM)

-$42.21M

Year Range

$0.51 - $2.45

Target Price

$7.25

Short %

1.52%

Short Ratio

1.13

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Cortexyme Inc

Popular comparisons:
QNCX vs. DAL
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

Cortexyme Inc (QNCX) returned -44.39% year-to-date (YTD) and 24.95% over the past 12 months.


QNCX

YTD

-44.39%

1M

-5.45%

6M

-49.27%

1Y

24.95%

3Y*

-26.22%

5Y*

-53.15%

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of QNCX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-13.90%-9.94%-8.28%-17.29%-5.45%-44.39%
202418.10%4.84%-18.46%0.94%-22.43%-9.64%-0.01%-7.85%12.33%108.71%26.54%-8.78%78.10%
202353.85%-5.31%68.10%-1.92%-1.96%0.33%-20.27%9.17%-14.50%-13.30%-8.34%17.98%64.84%
2022-51.82%-28.45%42.30%-40.87%-29.23%-14.29%-12.16%-9.74%-24.43%-24.81%-26.30%-13.57%-94.95%
202141.18%-13.13%5.75%8.71%5.62%28.11%6.62%70.41%-4.82%-85.60%-1.44%-3.00%-54.57%
2020-16.30%6.94%-9.23%0.02%1.03%0.46%-13.93%10.34%13.71%-4.26%1.52%-42.84%-50.52%
2019-21.95%65.60%-16.73%-43.93%25.59%-16.69%26.38%113.87%70.69%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of QNCX is 64, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of QNCX is 6464
Overall Rank
The Sharpe Ratio Rank of QNCX is 6262
Sharpe Ratio Rank
The Sortino Ratio Rank of QNCX is 6969
Sortino Ratio Rank
The Omega Ratio Rank of QNCX is 6565
Omega Ratio Rank
The Calmar Ratio Rank of QNCX is 6262
Calmar Ratio Rank
The Martin Ratio Rank of QNCX is 6262
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Cortexyme Inc (QNCX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Cortexyme Inc Sharpe ratios as of May 31, 2025 (values are recalculated daily):

  • 1-Year: 0.28
  • 5-Year: -0.55
  • All Time: -0.44

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Cortexyme Inc compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Cortexyme Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Cortexyme Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cortexyme Inc was 99.55%, occurring on Aug 15, 2024. The portfolio has not yet recovered.

The current Cortexyme Inc drawdown is 99.13%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.55%Aug 11, 2021758Aug 15, 2024
-61.69%Feb 18, 2020222Dec 31, 2020151Aug 9, 2021373
-56.16%Jul 2, 201943Aug 30, 201977Dec 19, 2019120
-38.11%Dec 24, 20199Jan 7, 202027Feb 14, 202036
-27.46%May 10, 20191May 10, 201925Jun 17, 201926
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Cortexyme Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Cortexyme Inc, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -47.8%.


-0.80-0.60-0.40-0.200.0020212022202320242025
-0.34
-0.23
Actual
Estimate

Valuation

The Valuation section provides an overview of how Cortexyme Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for QNCX relative to other companies in the Biotechnology industry. Currently, QNCX has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for QNCX in comparison with other companies in the Biotechnology industry. Currently, QNCX has a P/B value of 2.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items